<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75598">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970644</url>
  </required_header>
  <id_info>
    <org_study_id>B2013:129</org_study_id>
    <nct_id>NCT01970644</nct_id>
  </id_info>
  <brief_title>Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases</brief_title>
  <official_title>Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Sciences Centre Foundation, Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CancerCare Manitoba</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer which spreads to the brain (brain metastases) is a common and significant problem.
      Historically, whole-brain radiotherapy has been used to treat these patients but has a
      negative effect on cognition.  Radiosurgery is an alternative treatment with potential for
      fewer cognitive side effects.  The impact of radiosurgery alone on the cognitive function of
      patients with multiple brain metastases is not well studied.  We propose a pilot study at
      the Winnipeg Centre for Gamma Knife Surgery to examine this issue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with &gt;=4 brain metastases will undergo Gamma Knife radiosurgery to a dose of 15-20
      Gy, depending on the maximum tumour diameter and number of metastases.  A number of
      neurocognitive, quality of life, and toxicity assessments will be performed at baseline and
      at 6 weeks post-radiosurgery, then at months 4, 6, 12, 18, and every 6 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Hopkins Verbal Learning Test - Revised (HVLT-R)</measure>
    <time_frame>4 months after radiosurgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive battery</measure>
    <time_frame>4 months after radiosurgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Other neurocognitive tests will include Trail making test A and B (TMT), Controlled Oral Word Association (COWAT), Test of Premorbid Functioning, Ruff Figural Fluency Test, Animal Naming, Brief Visuospatial Memory Test - Revised, WMS-III Digit Span, WMS-III Spatial Span, and the Symbol Digit Modalities Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>4 months after radiosurgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative (QLQ-C15-PAL)
Brain cancer specific quality of life questionnaire (QLQ-BN20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Terminology Criteria for Adverse Events (CTCAE) v4.0</measure>
    <time_frame>4 months after radiosurgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to in-field and distant radiographic progression</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Duration of functional independence (Barthel ADL index)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Neurologic death rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Neoplasm Metastases</condition>
  <arm_group>
    <arm_group_label>Brain metastases (&gt;= 4)</arm_group_label>
    <description>Patients with pathologically proven solid tumour malignancy who have &gt;=4 brain metastases will be treated with gamma knife radiosurgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gamma knife radiosurgery</intervention_name>
    <description>Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.</description>
    <arm_group_label>Brain metastases (&gt;= 4)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with multiple (&gt;= 4) brain metastases undergoing radiosurgery at the Winnipeg
        Centre for Gamma Knife Surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven solid tumour malignancy

          -  Age &gt;= 18 years

          -  Karnofsky performance status &gt;= 70

          -  &gt;= 4 brain metastases, all eligible to be treated with radiosurgery

          -  All brain metastases &lt;= 4.0 cm in any diameter

          -  Pre-treatment contrast enhanced MRI brain &lt;= 42 days prior to enrollment

          -  Patient able to provide his/her own written informed consent

        Exclusion Criteria:

          -  Prior radiosurgery, whole brain radiotherapy, or cranial radiotherapy

          -  Previous surgical resection of brain metastasis (biopsy is allowed)

          -  Prior chemotherapy â‰¤ 7 days prior to enrollment

          -  Planned chemotherapy during radiosurgery

          -  Leukemia, lymphoma, germ-cell tumour, small-cell lung cancer diagnosis

          -  Brainstem metastasis

          -  Leptomeningeal metastases

          -  Contraindication to MR imaging with contrast

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harvey Quon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CancerCare Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harvey Quon, MD</last_name>
    <phone>(204) 787-1400</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael West, MD</last_name>
    <phone>(204) 787-7960</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Sciences Centre / CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Harvey Quon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CancerCare Manitoba</investigator_affiliation>
    <investigator_full_name>Harvey Quon</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Neoplasm metastasis</keyword>
  <keyword>Brain neoplasms</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Cognition disorders</keyword>
  <keyword>Cranial irradiation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
